Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma

Abstract The multicenter, phase Ib CC‐122‐DLBCL‐001 dose‐expansion study (NCT02031419) explored the cereblon E3 ligase modulator (CELMoD) agent avadomide (CC‐122) plus rituximab in patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) or follicular lymphoma (FL). Patients rec...

Full description

Bibliographic Details
Main Authors: Loretta J. Nastoupil, John Kuruvilla, Julio C. Chavez, Fontanet Bijou, Thomas E. Witzig, Armando Santoro, Ian W. Flinn, Carola Boccomini, Vaishalee P. Kenkre, Paolo Corradini, Iris Isufi, David J. Andorsky, Leonard M. Klein, Daniel R. Greenwald, Randeep Sangha, Frank Shen, Patrick Hagner, Yan Li, Juergen Dobmeyer, Nian Gong, Shailaja Uttamsingh, Michael Pourdehnad, Vincent Ribrag
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:eJHaem
Subjects:
avadomide
CELMoD
diffuse large B‐cell lymphoma
follicular lymphoma
Online Access:https://doi.org/10.1002/jha2.394

Similar Items

Similar Items